secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wellgistics Health, Inc. (WGRX)
CIK:        0002030763
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001493152-25-026652
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wellgistics launches Brenzavvy targeting $16B SGLT-2 inhibitor market
---------------------------------------------------------------------

- Brenzavvy launch targets 33M type II diabetics in US with out-of-pocket costs above cash price.
- EinsteinRx AI platform alerts pharmacists to patients with Class 1A recommendation for SGLT-2 inhibitors.
- Pharmacist-led provider education model aims to improve patient access and create revenue opportunity for pharmacists.
- Wellgistics network includes 6,500+ independent pharmacies primarily in rural communities.
- SGLT-2 inhibitor market reached $16.8B in 2024; US represents 40.8% of market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2030763/000149315225026652/0001493152-25-026652-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2030763/000149315225026652/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-026652

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer